Methylthio-DADMe-Immucillin-A (MTDIA) is an 86 pM transition state analogue of human
5¢-methylthioadenosine phosphorylase (MTAP). 5¢-Methylthioadenosine (MTA) is formed
in polyamine synthesis and is recycled by MTAP to S-adenosyl-l-methionine (SAM) via salvage pathways. MTDIA treatment causes accumulation
of MTA, an inhibitor of human head and neck (FaDu) and lung (H359, A549) cancers in
immunocompromised mouse models. We investigated the efficacy of oral MTDIA as an anti-cancer
therapeutic for intestinal adenomas in immunocompetent APCMin/+ mice, a murine model of human Familial Adenomatous Polyposis. APCMin/+ mouse lifespan nearly doubled when treated with an optimal daily oral dose of 20
mg/kg/day MTDIA. Oral MTDIA reduced tumor burden and markedly improved anemia. Metabolomic
analysis of treated mice showed no changes in polyamine, methionine, SAM or ATP levels
when compared with control mice but indicated a >4-fold increase in levels of MTA,
the MTAP substrate. In vitro experiments generated an MTDIA-resistant FaDu cell line in culture. Genomic analysis
of resistant cells showing 4-fold gene amplification of the methionine adenosyl transferase
(MAT2A) locus. We hypothesize that MTDIA exerts its anti-cancer effects by increasing cellular
concentrations of MTA, inhibiting PRMT5-mediated histone methylation and intron splicing
to slow cancer cell growth. Oral dosing of MTDIA may provide a monotherapy for delaying
the onset and progression of colorectal cancers in Familial Adenomatous Polyposis.
MTDIA causes a chemical knock-out of MTAP and may therefore also have efficacy in
combination with inhibitors of MAT2A or PRMT5, known synthetic-lethal interactions
in cancer cell lines.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2020 Elsevier B.V. Published by Elsevier Inc. All rights reserved.